| Zacks Company Profile for Synovics Pharmaceuticals Inc. (SYVC : OTC) |
|
|
| |
| • Company Description |
| Synovics Pharmaceuticals, Inc. (formerly Bionutrics Inc.), through its subsidiaries, develops, manufactures, and commercializes generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products. The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It also offers private label solid dosage Rx products, including Estratest, a product used by post-menopausal women. The company packages and distributes its private label, or store brand OTC products to chain drug stores, wholesalers, and distributors in the United States. It primarily has strategic alliance agreement with Maneesh Pharmaceuticals Pvt., Ltd. and Harcharan (Harry) Singh. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: 0.53 |
| 52 Week High: $0.00 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
% |
% |
| 12 Week |
% |
% |
| Year To Date |
% |
% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
5360 NORTHWEST 35TH AVENUE
-
FT. LAUDERDALE,FL 33309
USA |
ph: 954-486-4590
fax: - |
None |
None |
|
|
| |
| • General Corporate Information |
Officers
Ronald H. Lane - Chairman of the Board
Jyotindra Gange - Principal Executive Officer; Director
Mahendra Desai - Chief Financial Officer
Vinay Sapte - Director
Vinay Sapte - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 87163M101
SIC: 2833
|
|
Fiscal Year
Fiscal Year End: October
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 0.53
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
